MC1220A1
(fr)
*
|
1977-10-28 |
1979-07-20 |
Hoffmann La Roche |
Nouveaux derives d'imidazolidine
|
IL55774A
(en)
*
|
1977-10-28 |
1982-04-30 |
Sparamedica Ag |
Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
|
FI801184A
(fi)
*
|
1979-04-24 |
1980-10-25 |
Hoffmann La Roche |
Foerfarande foer framstaellning av imidazolidinderivat
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
EP0195015B1
(en)
*
|
1984-08-02 |
1992-05-13 |
LABRIE, Fernand |
Pharmaceutical composition for combination therapy of hormone dependent cancers
|
US4775660A
(en)
*
|
1984-08-02 |
1988-10-04 |
Fernand Labrie |
Treatment of breast cancer by combination therapy
|
US5084472A
(en)
*
|
1986-11-04 |
1992-01-28 |
Roussel |
Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
|
IT1214735B
(it)
*
|
1986-11-04 |
1990-01-18 |
Roussel Maestretti Spa |
Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
|
FR2619381B1
(fr)
*
|
1987-08-13 |
1989-12-08 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
FR2656302B1
(fr)
*
|
1989-12-22 |
1992-05-07 |
Roussel Uclaf |
Nouveau procede de preparation de l'anandron et derives de l'anandron.
|
US5411981A
(en)
*
|
1991-01-09 |
1995-05-02 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
FR2693461B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
FR2671348B1
(fr)
*
|
1991-01-09 |
1993-03-26 |
Roussel Uclaf |
Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
|
USRE35956E
(en)
*
|
1991-01-09 |
1998-11-10 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
US6002016A
(en)
*
|
1991-12-20 |
1999-12-14 |
Rhone-Poulenc Agrochimie |
Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
|
FR2685328B1
(fr)
*
|
1991-12-20 |
1995-12-01 |
Rhone Poulenc Agrochimie |
Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
FR2706456B1
(fr)
*
|
1993-06-18 |
1996-06-28 |
Rhone Poulenc Agrochimie |
Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
FR2694290B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
US6008370A
(en)
*
|
1992-11-25 |
1999-12-28 |
Rhone-Poulenc Agrochimie |
Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
|
FR2715402B1
(fr)
*
|
1994-01-05 |
1996-10-04 |
Roussel Uclaf |
Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
TW521073B
(en)
*
|
1994-01-05 |
2003-02-21 |
Hoechst Marion Roussel Inc |
New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
|
FR2724169B1
(fr)
*
|
1994-09-06 |
1997-01-03 |
Roussel Uclaf |
Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
FR2725206B1
(fr)
*
|
1994-09-29 |
1996-12-06 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
US5656651A
(en)
*
|
1995-06-16 |
1997-08-12 |
Biophysica Inc. |
Androgenic directed compositions
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
US20040077605A1
(en)
*
|
2001-06-20 |
2004-04-22 |
Salvati Mark E. |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
CZ20024214A3
(cs)
*
|
2000-06-28 |
2003-04-16 |
Bristol-Myers Squibb Company |
Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití
|
US7001911B2
(en)
|
2000-06-28 |
2006-02-21 |
Bristol-Myers Squibb Company |
Fused cyclic modulators of nuclear hormone receptor function
|
US6953679B2
(en)
|
2000-09-19 |
2005-10-11 |
Bristol-Myers Squibb Company |
Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
|
EP1854798A3
(en)
|
2000-09-19 |
2007-11-28 |
Bristol-Myers Squibb Company |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
US20040087548A1
(en)
|
2001-02-27 |
2004-05-06 |
Salvati Mark E. |
Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
US7015253B2
(en)
*
|
2001-07-10 |
2006-03-21 |
American Medical Systems, Inc. |
Regimen for treating prostate tissue and surgical kit for use in the regimen
|
PL206962B1
(pl)
*
|
2001-12-19 |
2010-10-29 |
Bristol Myers Squibb Co |
Związek heterocykliczny o budowie skondensowanej
|
US7354933B2
(en)
*
|
2003-01-31 |
2008-04-08 |
Aventis Pharma Sa |
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
FR2850652B1
(fr)
*
|
2003-01-31 |
2008-05-30 |
Aventis Pharma Sa |
Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
EP1656142A4
(en)
*
|
2003-08-22 |
2011-06-22 |
Ligand Pharm Inc |
6-CYCLOAMINO-2-QUINOLINONE DERIVATIVES AS MODULATORS ANDROGEN RECEPTOR COMPOUNDS
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
CA2550447A1
(en)
*
|
2003-12-19 |
2005-07-07 |
The Regents Of The University Of California |
Methods and materials for assessing prostate cancer therapies
|
AU2005232526B2
(en)
*
|
2004-02-24 |
2011-06-23 |
The Regents Of The University Of California |
Methods and materials for assessing prostate cancer therapies and compounds
|
WO2005090282A1
(en)
*
|
2004-03-12 |
2005-09-29 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
EP1791821B1
(en)
*
|
2004-09-10 |
2013-06-05 |
Janssen Pharmaceutica NV |
Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
EP1893196B2
(en)
|
2005-05-13 |
2015-07-29 |
The Regents of The University of California |
Diarylhydantoin compound
|
CA2598216C
(en)
*
|
2005-06-17 |
2014-04-08 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
FR2896503B1
(fr)
*
|
2006-01-23 |
2012-07-13 |
Aventis Pharma Sa |
Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
SI2368550T1
(sl)
|
2006-03-27 |
2013-11-29 |
The Regents Of The University Of California |
Modulator androgenskih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenskimi receptorji
|
MX2008012492A
(es)
|
2006-03-29 |
2008-12-12 |
Univ California |
Compuestos de diariltiohidantoina.
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
US20220096112A1
(en)
|
2007-01-02 |
2022-03-31 |
Aquabeam, Llc |
Tissue resection with pressure sensing
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
ES2858596T3
(es)
|
2007-01-02 |
2021-09-30 |
Aquabeam Llc |
Dispositivos mínimamente invasivos para el tratamiento de enfermedades de la próstata
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
JP5535925B2
(ja)
|
2007-10-26 |
2014-07-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
|
ES2769535T3
(es)
|
2008-03-06 |
2020-06-26 |
Aquabeam Llc |
Ablación de tejido y cauterización con energía óptica transportada en una corriente de fluido
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
US10524822B2
(en)
|
2009-03-06 |
2020-01-07 |
Procept Biorobotics Corporation |
Image-guided eye surgery apparatus
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
FR2944524B1
(fr)
|
2009-04-17 |
2012-11-30 |
Ipsen Pharma Sas |
Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
|
DK3124481T3
(en)
|
2010-02-16 |
2018-05-07 |
Aragon Pharmaceuticals Inc |
ANDROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
|
ES2634669T3
(es)
|
2011-02-08 |
2017-09-28 |
Halozyme, Inc. |
Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
|
CN104203078B
(zh)
|
2012-02-29 |
2018-04-20 |
普罗赛普特生物机器人公司 |
自动化图像引导的组织切除和处理
|
IL312316A
(en)
|
2012-09-26 |
2024-06-01 |
Aragon Pharmaceuticals Inc |
Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
ES2798899T3
(es)
|
2013-02-25 |
2020-12-14 |
Novartis Ag |
Mutación novedosa del receptor de andrógenos
|
BR112016005036A2
(pt)
|
2013-09-06 |
2020-04-07 |
Procept Biorobotics Corp |
aparelho para ressecção de tecido guiada por imagem automatizada
|
JP6651471B2
(ja)
|
2014-06-30 |
2020-02-19 |
プロセプト バイオロボティクス コーポレイション |
流体ジェット組織アブレーションおよび冷凝固(aquablation)方法および装置
|
JP2017532095A
(ja)
|
2014-09-05 |
2017-11-02 |
プロセプト バイオロボティクス コーポレイション |
標的器官画像の処理マッピングと一体化された医師制御組織切除
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
US20190209469A1
(en)
|
2016-08-20 |
2019-07-11 |
Ftf Pharma Private Limited |
Pharmaceutical composition comprising an androgen receptor inhibitor
|
CN107216290B
(zh)
*
|
2017-06-12 |
2021-03-16 |
陕西科技大学 |
一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
|
KR20200070334A
(ko)
|
2017-10-16 |
2020-06-17 |
아라곤 파마슈티컬스, 인코포레이티드 |
비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
|